Journal
DIAGNOSTIC PATHOLOGY
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1746-1596-8-1
Keywords
miR-372; Glioma; Real-time quantitative RT-PCR assay; Prognosis
Categories
Funding
- National Natural Science Foundation of China [81272776]
- China Postdoctoral Science Foundation [20100471628, 201104634]
- Wu Jieping Foundation [320.6750.12161]
- Shaanxi Province Programs for Science and Technology Development [2012K 13-01-13, 2011K12-47]
- Tangdu hospital, the Fourth Military Medical University
Ask authors/readers for more resources
MicroRNA-372 (miR-372) acts as either an oncogenic miRNA or an anti-oncomiR in various human malignancies. However, its roles in gliomas have not been elucidated. To address this problem, we here detected miR-372 expression in human gliomas and non-neoplastic brain tissues by real-time quantitative RT-PCR assay. The association of miR-372 expression with clinicopathological factors or prognosis of glioma patients was also statistically analyzed. As the results, miR-372 expression levels were significantly upregulated in glioma tissues compared to the corresponding non-neoplastic brain tissues (P < 0.001). In addition, the high miR-372 expression was significantly associated with the advanced pathological grade (P = 0.008) and the low Karnofsky performance score (KPS) of glioma patients (P = 0.01). Moreover, the overall survival of patients with high miR-372 expression was dramatically shorter than those with low miR-372 expression (P < 0.001). Furthermore, multivariate Cox regression analysis indicated that miR-372 expression was an independent prognostic factor for glioma patients (P = 0.008). More importantly, subgroup analyses according to tumor pathological grade revealed that the cumulative overall survival of glioma patients with advanced pathological grades was significantly worse for high miR-372 expression group than for low miR-372 expression group (P < 0.001), but no significant difference was found for patients with low pathological grades (P = 0.08). Taken together, these data offer the convincing evidence for the first time that miR-372 may act as an oncogenic miRNA in gliomas and represent a potential regulator of aggressive development and a candidate prognostic marker for this malignancy, especially for advanced tumors with high pathological grades.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available